<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2605222072
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DETRUSITOL RETARD 2 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOLTERODINE TARTRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        71.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            VIATRIS PHARMA S.R.L.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BD07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Detrusitol Retard is tolterodine. Tolterodine belongs to the group of medicines called antimuscarinics.</p><p>Detrusitol Retard is used in the symptomatic treatment of Overactive Bladder Syndrome. If you suffer from overactive bladder syndrome you will notice an inability to control micturition (urination), the need to hurry to the toilet frequently without any warning signs.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Detrusitol Retard</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to tolterodine or to any of the excipients of this medicine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are unable to empty your bladder (urinary retention)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have uncontrolled narrow-angle glaucoma (high eye pressure with loss of vision, not treated adequately)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from myasthenia gravis (excessive muscle weakness)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from severe ulcerative colitis (ulcer and inflammation of the colon)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from toxic megacolon (acute dilatation of the colon)</p><p>&nbsp;</p><p><strong>Pay close attention with Detrusitol Retard</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have difficulty urinating and/or have a poor urinary stream</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have gastrointestinal disorders that affect the passage and/or digestion of foods</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have kidney problems (kidney failure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have liver problems<s> </s></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from nervous diseases, which affect blood pressure, the intestines and sexual function (any neuropathy of the autonomic nervous system)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a hiatal hernia (herniation of an abdominal organ)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from decreased intestinal motility or from severe constipation (decreased gastrointestinal motility)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have heart problems, including:</p><p>o&nbsp;&nbsp; Altered electrocardiogram (ECG)</p><p>o&nbsp;&nbsp; Slow heart rate (bradycardia)</p><p>o&nbsp;&nbsp; Significant pre-existing heart diseases, including:</p><p>- cardiomyopathy (weakening of the heart muscle)</p><p>- myocardial ischaemia (reduced blood flow to the heart)</p><p>- arrhythmia (irregular heartbeat)</p><p>- and heart failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have particularly low levels of potassium (hypopotassaemia), calcium (hypocalcaemia) or magnesium (hypomagnesaemia) in your blood.</p><p>&nbsp;</p><p>If any of these cases pertain to you, tell your doctor or pharmacist before starting treatment.</p><p><strong>Other medicines and Detrusitol Retard</strong></p><p>Tolterodine, the active substance in Detrusitol Retard, can interact with other medicines.</p><p>The use of tolterodine is not recommended with the following medicines:</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antibiotics (containing, for example, erythromycin, clarithromycin);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for the treatment of fungal infections (such as ketoconazole, itraconazole);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat HIV.</p><p>&nbsp;</p><p>Detrusitol Retard must be used with caution when taken in combination with:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that affect the passage of food (containing, for example, metoclopramide and cisapride)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for the treatment of irregular heartbeat (containing, for example, amiodarone, sotalol, quinidine, procainamide)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines with a similar mode of action to Detrusitol Retard (antimuscarinic properties) or medicines with an opposite mode of action to Detrusitol Retard (cholinergic properties). If you have any further questions, ask your doctor.</p><p>&nbsp;</p><p>Tell your doctor if you are taking or have recently taken any other medicines, even medicines that do not require a doctor&rsquo;s prescription.</p><p>&nbsp;</p><p><strong>Detrusitol Retard with food and drink</strong></p><p>Detrusitol Retard can be taken before, during or after meals.</p><p>Pregnancy and breast-feeding</p><p><strong>Pregnancy </strong></p><p>Do not take Detrusitol Retard if you are pregnant. Contact your doctor immediately if you are pregnant, think you may be pregnant or are planning to become pregnant.</p><p><strong>Breast-feeding</strong></p><p>No data are available on the excretion of tolterodine into breast milk. Breast-feeding is not recommended while taking Detrusitol Retard.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong></p><p>Detrusitol Retard may cause dizziness, tiredness or affect your eyesight. Your ability to drive or use machines may be impaired.</p><p>&nbsp;</p><p><strong>Important information about some of the excipients of Detrusitol Retard</strong></p><p>This medicine contains sucrose (a type of sugar). If you have been diagnosed with intolerance to certain sugars, talk to your doctor before taking this medicine. Patients with rare hereditary problems of intolerance to galactose, such as galactosaemia or with glucose-galactose malabsorption, should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>Dosage</u></p><p>Always take Detrusitol Retard exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended dose is one 4 mg prolonged-release capsule daily, except for patients with kidney or liver problems or those who experience side effects. In these cases the doctor may reduce the dose to one 2 mg prolonged-release capsule daily.</p><p>&nbsp;</p><p>Detrusitol Retard is not recommended for children.</p><p>&nbsp;</p><p>These prolonged-release capsules are for oral use and must be swallowed whole. Do not chew these capsules.</p><p>&nbsp;</p><p><u>Treatment time</u></p><p>Your doctor will tell you how long to take Detrusitol Retard. Do not discontinue the treatment early as it does not take effect immediately. It will take time for your bladder to adapt. Complete the treatment cycle of prolonged-release capsules prescribed by your doctor. Talk to your doctor if you have not experienced any benefits by that time.</p><p>&nbsp;</p><p>The treatment benefits should be reassessed after 2 or 3 months.</p><p>&nbsp;</p><p><strong>Always talk to your doctor if you plan to discontinue the treatment. </strong></p><p>&nbsp;</p><p><strong>If you take more Detrusitol Retard than you should</strong></p><p>If you or someone else has taken too many prolonged-release capsules, contact your doctor or pharmacist right away.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Detrusitol Retard</strong></p><p>If you forget to take a dose at the usual time, you may take it as soon as you remember, unless it is almost time to take the next dose. If this is the case, do not take the forgotten dose and continue with the normal dosage regimen.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Detrusitol Retard can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Go to your doctor&rsquo;s office or to the emergency room immediately if angioedema symptoms should appear, including:</p><p>o&nbsp;&nbsp; swelling of the face, tongue or pharynx</p><p>o&nbsp;&nbsp; difficulty swallowing</p><p>o&nbsp;&nbsp; hives and difficulty breathing</p><p>&nbsp;</p><p>You should also contact your doctor if you experience hypersensitivity reactions (such as itching, rash, hives, difficulty breathing). These reactions are uncommon (occur in fewer than 1 patient in 100).</p><p>&nbsp;</p><p>Tell your doctor immediately or go to the emergency room if you notice any of the following symptoms:</p><ul><li>chest pain, difficulty breathing or tendency to tire easily (even when resting), difficulty breathing at night, swelling in your legs.</li></ul><p>These can be symptoms of heart failure. These symptoms are uncommon (occur in fewer than 1 patient in 100).</p><p>&nbsp;</p><p>The following side effects have been reported during treatment with Detrusitol Retard with the following frequency:</p><p>&nbsp;</p><p><strong>Very common side effects </strong>(occur in more than 1 patient in 10):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth</p><p>&nbsp;</p><p><strong>Common side effects </strong>(occur in fewer than 1 patient in 10):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinusitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, sleepiness, headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry eyes, blurred vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digestion problems (dyspepsia), constipation, abdominal pain, excessive amounts of air or gas in the stomach or in the intestines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful or difficult urination</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Presence of excess bodily fluids that cause swelling (such as ankles)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(occur in fewer than 1 patient in 100):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervousness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling sensations (pins and needles) in hands and feet</p><p>-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;Vertigo</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations, heart failure, irregular heartbeat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability to empty the bladder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired memory</p><p><em><s>&nbsp;</s></em></p><p>Other reported reactions include severe allergic reactions, confusion, hallucinations, rapid heartbeat, reddening of the skin, heartburn, vomiting, angioedema, dry skin and disorientation.</p><p>Cases of worsening of the symptoms of dementia in patients treated for dementia have also been reported.</p><p>If any of the side effects gets worse, or if you notice the appearance of any side effects not listed in this leaflet, tell your doctor or pharmacist.</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side affects you can help provide more information on the safety of this medicine.</p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:324px"><tbody><tr><td style="vertical-align:top; width:321px"><p>The National Pharmacovigilance Center (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> </strong><strong>GCC States</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use Detrusitol Retard after the expiry date stated on the pack. The expiry date refers to the last day of the month.</p><p>Store below 25 &deg;C.</p><p>Bottles: store in the original container.</p><p>Blisters: store blisters in the original pack.</p><p>Do not dispose of any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance contained in Detrusitol Retard 2 mg prolonged-release capsules is 2 mg of tolterodine tartrate, equivalent to 1.37 mg of tolterodine</p><p>The active substance contained in Detrusitol Retard 4 mg prolonged-release capsules is 4 mg of tolterodine tartrate, equivalent to 2.74 mg of tolterodine</p><p>The excipients are:</p><p><em>Capsule contents:</em></p><p>Sugar spheres (containing sucrose and maize starch), hypromellose and Surelease E-7-19010 Clear (containing ethylcellulose, medium chain triglycerides and oleic acid)</p><p><em>Shell contents:</em></p><p>Gelatin and dyes</p><p><em>Dyes:</em></p><p>Blue-green in the 2 mg prolonged-release capsule: indigo carmine (E132), yellow iron oxide (E172), titanium dioxide (E171)</p><p>Blue in the 4 mg prolonged-release capsule: indigo carmine (E132), titanium dioxide (E171)</p><p><em>Printing ink: </em>Shellac, titanium dioxide (E171), propylene glycol, simethicone</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The 2 mg prolonged-release capsule, hard is blue-green with white imprint (symbol and 2). The 4 mg prolonged-release capsule, hard is blue with white imprint (symbol and 4).

Detrusitol Retard 2 mg and 4 mg prolonged-release capsules are available in the following packs:

Packs containing:
 

28 prolonged-release capsules 
 
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p><strong><em>Viatris Pharma S.r.l.(Via Vittor Pisani 20, Milano, CAP 20124- Italy )</em></strong>.</p><p><u>Manufacturer </u></p><p>Pfizer Italia S.r.l., Localit&agrave; Marino del Tronto - 63100 Ascoli Piceno (AP)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/2011
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في ديتروسيتول ريتارد هي تولتيرودين. ينتمي تولتيرودين إلى مجموعة من الأدوية تُسمَّى مضادات المسكارين.</p><p dir="RTL">يستخدم ديتروسيتول ريتارد لعلاج أعراض متلازمة فرط نشاط المثانة. إذا كنت تعاني من متلازمة فرط نشاط المثانة، فستلاحظ عدم قدرتك على التحكم في التبول (إخراج البول)، وحاجتك إلى الإسراع إلى الحمام بمعدل متكرر ودون أي علامات إنذارية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ديتروسيتول ريتارد</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية (فرط الحساسية) تجاه تولتيرودين أو أي من أسوغة هذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت غير قادر على إفراغ المثانة (احتباس البول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حالة خارجة عن السيطرة من زرق (جلوكوما) ضيق الزاوية (ارتفاع الضغط داخل العين مصحوب بفقدان للرؤية، ولم يتم علاجه بشكل ملائم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من وهن عضلي وَبيل (ضعف مفرط في العضلات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التهاب قولون تقرحي شديد (تقرح والتهاب في القولون)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تضخم القولون السمي (توسع حاد في القولون)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انتبه جيدًا عند استخدام ديتروسيتول ريتارد</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تواجه صعوبة عند التبول و/أو كان تدفق البول ضعيفًا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا باضطرابات معدية معوية تؤثر على مسار الطعام أو هضمه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات بالكلى (فشل الكلى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات بالكبد<s> </s></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض عصبية تؤثر على ضغط الدم والأمعاء والوظائف الجنسية (أي اعتلال عصبي للجهاز العصبي المستقل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك فتق حجابي (انفتاق في عضو بالبطن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض حركة الأمعاء أو من إمساك شديد (انخفاض الحركة المعدية المعوية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات بالقلب، بما في ذلك:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية في رسم القلب (ECG)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء معدل ضربات القلب (تباطؤ القلب)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض قلب مهمة موجودة بالفعل، بما في ذلك:</p><p dir="RTL">- اعتلال عضلة القلب (ضعف بعضلة القلب)</p><p dir="RTL">- إقفار بعضلة القلب (انخفاض تدفق الدم إلى القلب)</p><p dir="RTL">- عدم انتظام ضربات القلب (ضربات قلب غير منتظمة)</p><p dir="RTL">- وفشل القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مستويات منخفضة بشكل خاص من البوتاسيوم (نقص بوتاسيوم الدم) أو الكالسيوم (نقص كالسيوم الدم) أو المغنيسيوم (نقص مغنيسيوم الدم) في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبق أي من هذه الحالات عليك، فأخبر طبيبك أو الصيدلي بأمرها قبل بدء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وديتروسيتول ريتارد</strong></p><p dir="RTL">يُمكن لتولتيرودين، المادة الفعالة في ديتروسيتول ريتارد، أن يتفاعل مع أدوية اخرى.</p><p dir="RTL">لا ينصح باستخدام تولتيرودين مع الأدوية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية (التي تحتوي مثلًا على إريثرومايسين، كلاريثروميسين)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المُستخدمة لعلاج العدوى الفطرية (مثل كيتوكونازول، إتراكونازول)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج فيروس نقص المناعة البشرية (HIV).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب توخي الحذر عند استخدام ديتروسيتول ريتارد بالتزامن مع:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤثر على مسار الطعام (التي تحتوي مثلًا على ميتوكلوبراميد وسيسابريد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعالج عدم انتظام ضربات القلب (التي تحتوي مثلًا على أميودارون، سوتالول، كينيدين، بروكايناميد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لها طريقة عمل مشابهة لديتروسيتول ريتارد (خصائص مضادات المُسكارين) أو الأدوية التي لها طريقة عمل مخالفة لديتروسيتول ريتارد (خصائص كولينية). إذا كان لديك المزيد من الأسئلة، فاسأل طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت قد تلقيت مؤخرًا، أو تتلقى حاليًا، أي أدوية أخرى بما في ذلك الأدوية التي لا تتطلب وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول ديتروسيتول ريتارد مع الطعام والشراب</strong></p><p dir="RTL">يُمكن تناول ديتروسيتول ريتارد قبل الوجبات أو بعدها أو خلالها.</p><p dir="RTL">&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL"><strong>الحمل </strong></p><p dir="RTL">لا تتناولي ديتروسيتول ريتارد إذا كنتِ حاملًا. اتصلي بطبيبك على الفور إذا كنتِ حاملًا أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">لا توجد بيانات متاحة حول إفراز تولتيرودين في لبن الثدي. لا يُنصح بالرضاعة الطبيعية أثناء تناول ديتروسيتول ريتارد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يجب عليكِ استشارة طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يسبب ديتروسيتول ريتارد الدوار أو التعب أو قد يؤثر على بصرك. قد تختل قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات مهمة عن بعض أسوغة ديتروسيتول ريتارد</strong></p><p dir="RTL">هذا الدواء يحتوي على السكروز (وهو نوع من السكر). إذا تم تشخيصِك بعدم تحمل بعض أنواع السكريات، فاستشر طبيبك قبل تناول هذا الدواء. ينبغي على المرضى المصابين بمشكلات وراثية نادرة متعلقة بعدم تحمل الجلاكتوز، مثل وجود الجلاكتوز في الدم أو بسوء امتصاص الجلوكوز-الجلاكتوز، عدم تناول هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>الجرعة</u></p><p dir="RTL">ينبغي عليك دائمًا تناول ديتروسيتول ريتارد تمامًا كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي كبسولة 4 مجم واحدة ممتدة الإطلاق يوميًا، باستثناء في حالة المرضى المصابين بمشكلات في الكلى أو الكبد أو الذين يتعرضون لظهور آثار جانبية. وفي هذه الحالات، قد يقوم الطبيب بخفض الجرعة إلى كبسولة 2 مجم واحدة ممتدة الإطلاق يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينصح بتناول الأطفال لديتروسيتول ريتارد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه الكبسولات ممتدة الإطلاق مخصصة للاستخدام عن طريق الفم، ويجب بلعها كاملة. لا تقم بمضغ هذه الكبسولات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مدة العلاج</u></p><p dir="RTL">سيخبرك طبيبك بالمدة التي يجب عليك تناول ديتروسيتول ريتارد خلالها. لا تقم بإيقاف العلاج مبكرًا حيث إن تأثيره لا يبدأ في الظهور مباشرة. وستأخذ المثانة بعض الوقت لتتكيف. أكمل دورة العلاج التي وصفها الطبيب بالكبسولات ممتدة الإطلاق. تحدث مع طبيبك إذا لم تكن قد حققت أي استفادة بحلول ذلك الوقت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي إعادة تقييم فوائد العلاج بعد شهرين أو 3 أشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>احرص دومًا على استشارة طبيبك إذا كنت تنوي إيقاف العلاج. </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناولك جرعة من ديتروسيتول ريتارد أكبر مما ينبغي</strong></p><p dir="RTL">إذا تناولت أنت أو شخص آخر كمية أكبر مما ينبغي من الكبسولات ممتدة الإطلاق، فاتصل بطبيبك أو الصيدلي على الفور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حالة نسيانك تناول ديتروسيتول ريتارد</strong></p><p dir="RTL">في حالة نسيان تناول إحدى الجرعات في الميعاد المعتاد، فتناولها في أقرب وقت ممكن عندما تتذكر، ذلك ما لم يأت ميعاد الجرعة التي تليها. في هذه الحالة، لا تتناول الجرعة الفائتة واستمر في اتباع نظام الجرعات المعتاد.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة فائتة.</p><p dir="RTL">إذا كانت لديك المزيد من الأسئلة حول استخدام هذا المنتج، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب ديتروسيتول ريتارد آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اذهب إلى عيادة طبيبك أو إلى قسم الطوارئ على الفور إذا ظهرت أعراض التورم الوعائي، بما في ذلك:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو اللسان أو البلعوم</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة البلع</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى وصعوبة في التنفس</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عليك كذلك الاتصال بطبيبك إذا أصبت بتفاعلات فرط حساسية (مثل الحكة أو الطفح الجلدي أو الشرى أو صعوبة التنفس). هذه التفاعلات ليست شائعة (تصيب أقل من مريض واحد من كل 100 مريض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور أو اذهب إلى قسم الطوارئ إذا لاحظت ظهور أي من الأعراض التالية:</p><ul><li dir="RTL">ألم في الصدر أو صعوبة في التنفس أو ميل للإحساس بالتعب بسهولة (حتى أثناء الراحة) أو صعوبة في التنفس أثناء الليل أو تورم الساقين.</li></ul><p dir="RTL">فقد تكون هذه أعراضًا لفشل القلب. هذه الأعراض ليست شائعة (تصيب أقل من مريض واحد من كل 100 مريض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية أثناء العلاج بديتروسيتول ريتارد، وذلك بالمعدلات التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا </strong>(تصيب أكثر من مريض واحد من كل 10 مرضى):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL"><strong>آثار جانبية شائعة </strong>(تصيب أقل من مريض واحد من كل 10 مرضى):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجيوب الأنفية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار، النعاس، الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العين، تغيم الرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الهضم (سوء الهضم)، الإمساك، ألم البطن، كميات كبيرة من الهواء أو الغازات في المعدة أو الأمعاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو صعوبة في التبول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كمية مفرطة من السوائل الجسدية التي تسبب التورم (كما في الكاحلين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة </strong>(تصيب أقل من مريض واحد من كل 100 مريض):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العصبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالتنميل (الشكشكة والوخز) في اليدين والقدمين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخفقان، فشل القلب، عدم انتظام ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على إفراغ المثانة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال الذاكرة</p><p dir="RTL"><s>&nbsp;</s></p><p dir="RTL">تتضمن التفاعلات الأخرى المبلغ عنها، تفاعلات حساسية شديدة , التشوش , الهلاوس , سرعة ضربات القلب , احمرار الجلد , حرقة فم المعدة , القيء , التورم الوعائي , جفاف الجلد والتوهان. كذلك فقد تم الإبلاغ عن حالات لتفاقم أعراض الخرف لدى المرضى الذين يُعالجون من الخرف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تفاقمت حدة أي من الآثار الجانبية أو إذا ما لاحظت ظهور أي آثار جانبية لم ترد في هذه النشرة، فأخبر طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><br />إذا ظهرت عليك أي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يشتمل هذا على أي آثار جانبية محتملة وغير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول مأمونية هذا الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن الأعراض الجانبية</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">المركز الوطني للتيقظ الدوائي (NPC)</p><ul><li dir="RTL">مركز الاتصال الموحد: ۱۹۹۹۹</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</li></ul><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دول الخليج الأخرى</strong></p><p dir="RTL">يرجى الاتصال بالسلطة المختصة ذات الصلة.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم ديتروسيتول ريتارد بعد تاريخ انتهاء الصلاحية المُدون على العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يخزن في درجة أقل من ۲٥ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الزجاجات: تخزَّن في الحاوية الأصلية.</p><p dir="RTL">شرائط البليستر: يُخزن شريط البليستر في العبوة الأصلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي عن الطريقة المثلى للتخلص من أي أدوية لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة في كبسولات ديتروسيتول ريتارد 2 مجم ممتدة الإطلاق هي 2 مجم من طرطرات التولتيرودين، بما يكافئ 1.37 مجم من تولتيرودين.</p><p dir="RTL">المادة الفعالة في كبسولات ديتروسيتول ريتارد 4 مجم ممتدة الإطلاق هي 4 مجم من طرطرات التولتيرودين، بما يكافئ 2.74 مجم من تولتيرودين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأسوغة هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>محتويات الكبسولة:</em></p><p dir="RTL">كرات سكر (تحتوي على سكروز ونشاء الذرة)، وهيبروميلوز وسوريليز E-7-19010 صافي (يحتوي على إيثيل سيليولوز، وثلاثيات الجليسريد متوسطة السلسلة وحمض الأولييك)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>محتويات الغلاف:</em></p><p dir="RTL">جيلاتين وصبغات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الصبغات:</em></p><p dir="RTL">الأخضر المائل للزرقة في كبسولات 2 مجم ممتدة الإطلاق: قرمز نيلي (E132)، أكسيد الحديد الأصفر (E172) وثاني أكسيد التيتانيوم (E171)</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">الأزرق في كبسولات 4 مجم ممتدة الإطلاق: قرمز نيلي (E132)، ثاني أكسيد التيتانيوم (E171)</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>حبر الطباعة: </em>اللك وثاني أكسيد التيتانيوم (E171) وبروبيلين الجليكول وسيميثيكون</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كبسولات ديتروسيتول ريتارد ممتدة الإطلاق مخصصة للاستخدام بجرعات يومية.</p><p dir="RTL">كبسولة 2 مجم الصلبة ممتدة الإطلاق هي كبسولة خضراء مائلة للزرقة تحمل طباعة بيضاء (الرمز ورقم 2). كبسولة 4 مجم الصلبة ممتدة الإطلاق هي كبسولة زرقاء تحمل طباعة بيضاء (الرمز ورقم 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL">كبسولات ديتروسيتول ريتارد 2 مجم و4 مجم ممتدة الإطلاق متاحة في العبوات التالية:</p><p dir="RTL">28 كبسولة ممتدة الإطلاق</p><p dir="RTL">قد لا تُطرح جميع أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك تصريح التسويق</p><p dir="RTL">Viatris Pharma S.r.l.(Via Vittor Pisani 20, Milano, CAP 20124- Italy ).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الجهة المصنعة </u></p><p dir="RTL">Pfizer Italia S.r.l., Localit&agrave; Marino del Tronto - 63100 Ascoli Piceno (AP)</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير/شباط 2011
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DETRUSITOL Retard 2 mg prolonged-release capsules, hard
DETRUSITOL Retard 4 mg prolonged-release capsules, hard

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each prolonged-release hard capsule contains: tolterodine tartrate 2 mg or 4 mg which is equivalent to 1.37 mg and 2.74 mg of tolterodine, respectively.

Each 2 mg prolonged-release hard capsule contains up to 61.52 mg of sucrose.
Each 4 mg prolonged-release hard capsule contains up to 123.07 mg of sucrose.

For the complete list of excipients, please see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release capsule, hard.

The 2 mg prolonged-release capsule is blue-green with a white imprint (symbol and 2).
The 4 mg prolonged-release capsule is blue with a white imprint (symbol and 4).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic treatment of urge incontinence and/or of increased urinary frequency and urgency in</p><p>&nbsp;</p><p>patients with overactive bladder syndrome.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Adults (including elderly patients):</em></strong></p><p>The recommended dose is 4 mg once daily, except in patients with impaired liver function and severely impaired renal function (GFR <u>&lt;</u> 30 ml/min) for whom the recommended dose is 2 mg once daily (see sections 4.4 and 5.2). In case of uncomfortable side effects, the dose may be reduced from 4 mg to 2 mg daily.</p><p>&nbsp;</p><p>The prolonged-release hard capsule may be taken with or without food and must be swallowed whole.</p><p>&nbsp;</p><p>The effect of the treatment must be re-evaluated after 2-3 months (see section 5.1).<em> </em></p><p>&nbsp;</p><p><strong><em>Paediatric population:</em></strong></p><p>The efficacy of Detrusitol Retard has not been demonstrated in children (see section 5.1). Therefore, Detrusitol Retard is not recommended for children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tolterodine is contraindicated in patients with:
- Urinary retention
- Uncontrolled narrow-angle glaucoma
- Myasthenia gravis
- Known hypersensitivity to tolterodine or any of the excipients
- Severe ulcerative colitis 
- Toxic megacolon

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tolterodine must be used with caution in patients with:</p><p>&nbsp; - Significant bladder outlet obstruction with risk of urinary retention</p><p>&nbsp; - Gastrointestinal obstructive disorders, e.g. pyloric stenosis</p><p>&nbsp; - Renal impairment (see sections 4.2 and 5.2)</p><p>&nbsp; - Hepatic disease (see sections 4.2 and 5.2)</p><p>&nbsp; - Autonomic neuropathy</p><p>&nbsp; - Hiatus hernia</p><p>&nbsp; - Risk of decreased gastrointestinal motility</p><p>&nbsp;</p><p>Multiple daily doses of immediate-release 4 mg (therapeutic) and 8 mg (supratherapeutic) tolterodine have been shown to prolong the QTc interval (see section 5.1). The clinical relevance of these findings is unclear and will depend on individual patient risk factors and sensitivities present. Tolterodine should be used with caution in patients with risk factors for QT interval prolongation, including:</p><p>&nbsp;</p><p>- Congenital or documented acquired QT prolongation</p><p>- Electrolyte disorders such as hypokalaemia, hypomagnesaemia and hypocalcaemia</p><p>- Bradycardia</p><p>- Relevant pre-existing coronary heart diseases (cardiomyopathy, myocardial ischaemia, arrhythmia, cardiac decompensation)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Concomitant administration of drugs that prolong QT interval, including Class 1A (e.g. quinidine, procainamide) and Class III (e.g. amiodarone, sotalol) anti-arrhythmics.</p><p>&nbsp;</p><p>This especially holds true when taking a potent CY3A4 inhibitor (see section 5.1). Concomitant treatment with potent CYP3A4 inhibitors should be avoided (see section 4.5 Interactions).</p><p>&nbsp;</p><p>As with all treatments for symptoms of urinary urgency or urge incontinence, any organic causes for urge and frequency should be considered before treatment.<strong><em> </em></strong></p><p>&nbsp;</p><p>Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>(erythromycin and clarithromycin), antifungal agents (ketoconazole and itraconazole) and protease inhibitors, is not recommended due to increased serum concentrations of tolterodine in poor CYP2D6 metabolisers with (subsequent) risk of overdose (see section 4.4).</p><p>Concomitant treatment with other drugs that possess antimuscarinic properties may result in more pronounced therapeutic effects and adverse reactions. Conversely, the therapeutic effect of tolterodine may be reduced following concomitant administration of muscarinic cholinergic receptor agonists.</p><p>&nbsp;</p><p>The effect of prokinetic drugs such as metoclopramide and cisapride may be reduced by tolterodine.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Concomitant treatment with fluoxetine (a potent CYP2D6 inhibitor), does not result in a clinically significant interaction, since tolterodine and its CYP2D6-dependent metabolite, 5-hydroxymethyl tolterodine, are equipotent.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Drug interaction studies have shown no interactions with warfarin or combined oral contraceptives (ethinyl estradiol/levonorgestrel).</p><p>A clinical trial has indicated that tolterodine is not a metabolic inhibitor of CYP2D6, 2C19, 2C9, 3A4 or 1A2. Therefore, an increase of plasma levels of drugs metabolised by these isoenzymes is not expected when administered in combination with tolterodine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em></p><p>There are no adequate data for the use of tolterodine in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>Consequently, DETRUSITOL Retard is not recommended during pregnancy.</p><p>&nbsp;</p><p><em><u>Breast-Feeding</u></em></p><p>No data concerning the excretion of tolterodine in human breast milk are available. Tolterodine should be avoided during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As this drug may cause accommodation disorders and affect reaction time, the ability to drive and use machines may be altered negatively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In view of its pharmacological effect, tolterodine may cause mild to moderate antimuscarinic effects, such as dry mouth, dyspepsia and dry eyes.</p><p>&nbsp;</p><p>The table below shows data obtained with DETRUSITOL Retard in clinical studies and data from post-marketing experience. The most commonly reported adverse reaction was dry mouth, which occurred in 23.4% of patients treated with DETRUSITOL Retard and in 7.7% of patients treated with placebo.</p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:90px"><p><strong>Very common</strong></p><p><strong>(&ge;1/10)</strong></p></td><td style="vertical-align:top; width:104px"><p><strong>Common</strong></p><p><strong>&ge;1/100 and &le;1/10</strong></p></td><td style="vertical-align:top; width:122px"><p><strong>Uncommon</strong></p><p><strong>&ge;1/1000 and &le;1/100</strong></p></td><td style="vertical-align:top; width:175px"><p><strong>Not known (frequency cannot be defined based on available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and Infestations</p></td><td style="vertical-align:top; width:90px"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>Sinusitis</p></td><td style="vertical-align:top; width:122px"><p>&nbsp;</p></td><td style="vertical-align:top; width:175px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune System</p><p>Disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top; width:90px"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&nbsp;</p></td><td style="vertical-align:top; width:122px"><p>Hypersensitivity not otherwise specified</p></td><td style="vertical-align:top; width:175px"><p>Anaphylactoid reactions</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top; width:90px"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top; width:122px"><p>Nervousness</p></td><td style="vertical-align:top; width:175px"><p>Confusion, hallucinations, disorientation</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System</p><p>Disorders</p></td><td style="vertical-align:top; width:90px"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>Dizziness, drowsiness, headache</p></td><td style="vertical-align:top; width:122px"><p>Paraesthesia, impaired memory</p></td><td style="vertical-align:top; width:175px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye Disorders</p></td><td style="vertical-align:top; width:90px"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>Dry eyes, abnormal vision (including abnormal adjustment)</p></td><td style="vertical-align:top; width:122px"><p>&nbsp;</p></td><td style="vertical-align:top; width:175px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and Labyrinth Disorders</p></td><td style="vertical-align:top; width:90px"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&nbsp;</p></td><td style="vertical-align:top; width:122px"><p>Vertigo</p></td><td style="vertical-align:top; width:175px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:90px"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&nbsp;</p></td><td style="vertical-align:top; width:122px"><p>Palpitations, cardiac insufficiency, arrhythmia</p></td><td style="vertical-align:top; width:175px"><p>Tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Vascular Disorders</p></td><td style="vertical-align:top; width:90px"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&nbsp;</p></td><td style="vertical-align:top; width:122px"><p>&nbsp;</p></td><td style="vertical-align:top; width:175px"><p>Erythema</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top; width:90px"><p>Dry mouth</p></td><td style="vertical-align:top; width:104px"><p>Dyspepsia, constipation, abdominal pain, flatulence, diarrhoea</p></td><td style="vertical-align:top; width:122px"><p>&nbsp;</p></td><td style="vertical-align:top; width:175px"><p>Gastroesophageal reflux, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p></td><td style="vertical-align:top; width:90px"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top; width:122px"><p>&nbsp;</p></td><td style="vertical-align:top; width:175px"><p>Angioedema, dry skin</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary Disorders</p></td><td style="vertical-align:top; width:90px"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>Dysuria</p></td><td style="vertical-align:top; width:122px"><p>Urinary retention</p><p>&nbsp;</p></td><td style="vertical-align:top; width:175px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General Disorders and Administration Site Conditions &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top; width:90px"><p>&nbsp;</p></td><td style="vertical-align:top; width:104px"><p>Fatigue, peripheral oedema</p></td><td style="vertical-align:top; width:122px"><p>Chest pain</p></td><td style="vertical-align:top; width:175px"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Cases of aggravation of symptoms of dementia (e.g. confusion, disorientation, delusions) have been reported after tolterodine therapy was initiated in patients taking cholinesterase inhibitors for the treatment of dementia.</p><p>&nbsp;</p><p><strong><em>Paediatric population</em></strong></p><p>In two phase III, randomised, placebo-controlled, double-blind paediatric studies conducted over 12 weeks in 710 paediatric patients, the proportion of patients with urinary tract infections, diarrhoea and abnormal behaviour was higher in patients treated with tolterodine than placebo (urinary tract infection: tolterodine 6.8%, placebo 3.6%; diarrhoea: tolterodine 3.3%, placebo 0.9%; abnormal behaviour: tolterodine 1.6%, placebo 0.4%) (see section 5.1).</p><p><strong>&nbsp;</strong></p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance and Drug Safety Centre ( NPC )</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other </strong><strong>GCC States</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Please contact the relevant competent authority.</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The highest dose given to healthy human volunteers of tolterodine tartrate is 12.8 mg as a single dose of the immediate-release formulation. The most severe adverse events observed were accommodation disorders and micturition difficulties.</p><p>&nbsp;</p><p>In the event of tolterodine overdose, treat with gastric lavage and administer activated charcoal.</p><p>Treat symptoms as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe central anticholinergic effects (e.g. hallucinations, severe excitation): administer physostigmine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions or pronounced excitation: administer benzodiazepines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory insufficiency: treat with artificial respiration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia: administer beta blockers.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary retention:&nbsp; treat with catheterisation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mydriasis: administer pilocarpine eye drops and/or keep patient in a dark room.</p><p>&nbsp;</p><p>An increase in QT interval was observed with a single daily dose of 8 mg immediate-release tolterodine (twice the recommended daily dose of standard formulation and equivalent to three times the peak exposure of the prolonged-release formulation) administered over 4 days. In the event of tolterodine overdose, standard supportive measures for managing QT prolongation should be adopted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: urinary antispasmodics.</p><p>ATC Code: G04BD</p><p>&nbsp;</p><p>Tolterodine is a competitive specific muscarinic receptor antagonist that demonstrates a selectivity for the urinary bladder over salivary glands <em>in vivo</em>. One of the tolterodine metabolites (5-hydroxymethyl derivative), shows a pharmacological profile similar to that of the parent compound. In fast metabolisers, this metabolite contributes significantly to the therapeutic effect of tolterodine (see section 5.2).</p><p>&nbsp;</p><p>The effects of the treatment can be expected within 4 weeks.</p><p>&nbsp;</p><p>In the Phase III programme, the primary endpont was reduction of the incontinence episodes per week, and the secondary endpoints were reduction of micturitions per 24 hours and increase in mean volume voided per micturition. These parameters are presented in the table below.</p><p>&nbsp;</p><p><strong>Effects of treatment with DETRUSITOL 4 mg Retard, once daily, after 12 weeks, compared with placebo. Absolute change and percentage change relative to baseline. Treatment difference between DETRUSITOL vs. placebo: Least Squares estimated mean change and 95% confidence interval.</strong></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | <strong>Detrusitol&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Significance&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | Retard 4 mg&nbsp; (n=508)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difference vs.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; statistical vs.</strong></p><p><strong>| 1 time/day&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; placebo: Variation&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; placebo (p-</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |&nbsp; (n=507)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mean and 95% CI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; value)</strong></p><p>_____________________________________________________________________________________________________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |</p><p>Number of incontinence|&nbsp; -11.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;0.001</p><p>episodes per week&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |&nbsp;&nbsp;&nbsp;&nbsp; (-54%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (-28%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (-7.2; -2.5)*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Number of micturitions | -1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -0.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.005&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per 24 hours&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; | (-13%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (-8%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (-1.0; -0.2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean volume voided per| +34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;0.001</p><p>micturition (ml) |&nbsp;&nbsp;&nbsp; (+27%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (+12%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (14; 26)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>_______________________________________________________________________________________________________</p><p><strong><em>* 97.5% confidence interval according to Bonferroni.</em></strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>After 12 weeks of treatment, 23.8% (121/507) in the DETRUSITOL Retard group and 15.7% (80/508) in the placebo group reported that they subjectively had minimal or no bladder problems.</p><p>&nbsp;</p><p>The effects of tolterodine were evaluated in patients, examined with urodynamic assessment at baseline and, depending on the urodynamic result, they were allocated to a urodynamic positive (motor urgency) or a urodynamic negative (sensory urgency) group. Within each group, patients were randomised to receive either tolterodine or placebo. The study did not provide convincing evidence that tolterodine had any effects over placebo in patients with sensory urgency.&nbsp;</p><p>&nbsp;</p><p>The clinical effects of tolterodine on QT interval are based on the ECGs obtained from over 600 treated patients, including elderly patients and patients with pre-existing cardiovascular disease. The changes in QT interval did not significantly differ between the placebo and treatment groups.</p><p>The effect of tolterodine on QT prolongation was investigated further in 48 healthy male and female volunteers aged 18-55 years. Subjects received 2 mg BID and 4 mg BID of tolterodine, immediate-release formulation. The results (Fridericia corrected) at peak tolterodine concentrations (1 hour) showed mean QTc interval increases of 5.0 and 11.8 msec for tolterodine doses of 2 mg BID and 4 mg BID respectively, and 19.3 msec for moxifloxacin (400 mg), which was used as the control drug. A pharmacokinetic/pharmacodynamic model has shown that the QTc interval increases in slow metabolisers (with no CYP2D6) treated with tolterodine 2 mg BID are comparable with those observed in fast metabolisers treated with 4 mg BID. At both doses of tolterodine, no subject, regardless of their metabolic profile, exceeded 500 msec for absolute QTcF or 60 msec for change from baseline. These changes are considered particularly significant threshold values. The 4 mg BID dose corresponds to a peak exposure (C<sub>max</sub>) of three times that obtained with the highest therapeutic dose of Detrusitol prolonged release capsules.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The efficacy in the paediatric population has not been demonstrated. Two paediatric phase 3 randomised, placebo-controlled, double-blind 12 week studies were conducted using tolterodine prolonged-release capsules. A total of 710 paediatric patients (486 on tolterodine and 224 on placebo) aged 5-10 years with increased urinary frequency and urinary urgency were studied.</p><p>No significant difference between the two groups was observed in either study with regard to change from baseline in total number of incontinence episodes/week (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacokinetic characteristics specific for this formulation</em>: Tolterodine prolonged-release capsules provide a slower absorption of tolterodine than the immediate-release tablets. As a result, maximum serum concentrations are observed 4 (2-6) hours after administration of the capsules. The apparent half-life of tolterodine administered in its capsule form is approximately 6 hours in fast metabolisers and approximately 10 hours in slow metabolisers (with CYP2D6 deficiency).</p><p>Steady state concentrations are reached within 4 days after administration of the capsules.</p><p>Food has no effect on the bioavailability of the capsules.</p><p>&nbsp;</p><p><em>Absorption:</em> After oral administration, tolterodine is subject to CYP2D6 catalysed first-pass metabolism in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically equipotent metabolite.</p><p>The absolute bioavailability of tolterodine is 17% in fast metabolisers and 65% in slow metabolisers (with CYP2D6 deficiency).</p><p>&nbsp;</p><p><em>Distribution</em>: Tolterodine and 5-hydroxymethyl metabolite bind primarily to orosomucoid.</p><p>The unbound fractions are 3.7% and 36%, respectively. The volume of distribution of tolterodine is 113 litres.</p><p>&nbsp;</p><p><em>Elimination:</em> Tolterodine is extensively metabolised by the liver following oral administration.</p><p>The primary metabolic route is mediated by the polymorphic enzyme CYP2D6 and leads to the formation of the 5-hydroxymethyl metabolite. Further metabolism leads to formation of the 5-carboxylic acid and N-dealkylated 5-carboxylic acid metabolites, which account for 51% and 29% of the metabolites recovered in the urine, respectively. A subset (about 7%) of the population has a CYP2D6 activity deficiency. The identified pathway of metabolism for these individuals (poor metabolisers) is dealkylation via CYP3A4 to N-dealkylated tolterodine, which does not cause any clinical effects.</p><p>The remainder of the population consists of fast metabolisers. The systemic clearance of tolterodine in fast metabolisers is approximately 30 L/h. In poor metabolisers the reduced clearance leads to significantly increased serum concentrations of tolterodine (approximately 7 times) and negligible concentrations of the 5-hydroxymethyl metabolite are observed.</p><p>&nbsp;</p><p>The 5-hydroxymethyl metabolite is pharmacologically active and equipotent with tolterodine.</p><p>Due to the differences in the protein-binding characteristics of tolterodine and the 5-hydroxymethyl metabolite, the exposure (AUC) of unbound tolterodine in poor metabolisers is similar to the combined exposure of unbound tolterodine and 5-hydroxymethyl derivative in patients with CYP2D6 activity, when the same dose is administered. The safety, tolerability and clinical response are similar, irrespective of phenotype.</p><p>&nbsp;</p><p>The excretion of radioactivity after administration of [<sup>14</sup>C]-tolterodine is approximately 77% in urine and 17% in faeces. Less than 1% of the dose is excreted as unchanged drug, and approximately 4% as the 5-hydroxymethyl metabolite. The carboxylated metabolite and the corresponding dealkylated metabolite account for about 51% and 29% of the urinary recovery, respectively.</p><p>&nbsp;</p><p>The pharmacokinetics is linear in the therapeutic dosage range.</p><p>&nbsp;</p><p><em>Specific patient groups:</em></p><p>Patients with liver impairment: about 2 times higher exposure of unbound tolterodine and its 5-hydroxymethyl metabolite is found in subjects with liver cirrhosis (see sections 4.2 and 4.4).</p><p>Patients with renal impairment: The mean exposure of unbound tolterodine and its 5-hydroxymethyl metabolite is doubled in patients with severe renal impairment [insulin clearance (GFR) <u>&lt;</u> 30 ml/min].</p><p>The plasma levels of other metabolites were markedly increased (up to 12 times) in these patients.</p><p>The clinical relevance of the increased exposure of these metabolites is unknown.</p><p>There is no data on mild to moderate renal impairment (see section 4.2 and 4.4).<strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Paediatric population</em></strong></p><p>The exposure of the active substance per mg/dose is similar in adults and adolescents. The mean exposure of the active substance per mg/dose is approximately two times higher in children between 5-10 years old than in adults (see sections 4.2 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In toxicity, genotoxicity, carcinogenicity and safety pharmacology studies, no clinically relevant effects have been observed, except those related to the pharmacological effects of the drug.</p><p>&nbsp;</p><p>Reprotoxicity studies have been performed in mice and rabbits.</p><p>In mice, there was no effect of tolterodine on fertility or reproductive function.</p><p>Tolterodine produced embryo death and foetal malformations at plasma exposures (C<sub>max</sub> or AUC) of 20 or 7 times higher than those seen in treated humans.</p><p>In rabbits, no effects on malformations were observed, but the studies were conducted at plasma exposure values (C<sub>max</sub> or AUC) that were 20 or 3 times higher than those expected in humans following the administration of therapeutic doses.</p><p>&nbsp;</p><p>Tolterodine, as well as its active human metabolites, prolongs action potential duration (90% repolarisation) in canine Purkinje fibres (14-75 times therapeutic levels) and blocks K+ flow in hERG (cloned human ether-a-go-go-related gene) channels (0.5 &ndash; 26.1 times therapeutic levels).</p><p>&nbsp;</p><p>In dogs, a slight prolongation of the QT interval has been observed following administration of tolterodine and its human metabolites (3.1 to 61.0 times therapeutic levels).</p><p>The clinical relevance of this effect is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Composition of prolonged-release capsule:</em></p><p>Sugar spheres (containing sucrose and maize starch)</p><p>Hypromellose</p><p><u>Surelease E-7-19010 clear</u>:</p><p>Ethylcellulose</p><p>Medium-chain triglycerides</p><p>Oleic acid</p><p>&nbsp;</p><p><em>Composition of prolonged-release capsule (shell):</em></p><p>Gelatin</p><p>&nbsp;</p><p><em>Printing ink:</em></p><p>Shellac</p><p>Titanium dioxide (E171)</p><p>Propylene glycol</p><p>Simethicone</p><p>&nbsp;</p><p><em>Dyes in 2 mg (blue-green) prolonged-release capsule:</em></p><p>Indigo carmine (E132)</p><p>Yellow iron oxide E172</p><p>Titanium dioxide (E171)</p><p>&nbsp;</p><p><em>Dyes in 4 mg (blue) prolonged-release capsule:</em></p><p>Indigo carmine (E132)</p><p>Titanium dioxide (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Detrusitol Retard  after the expiry date which is stated on the carton after EXP:. The expiry date refers to the last day of that month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not store at temperatures above 25 &deg;C.</p><p>Bottles: store in the original container.</p><p>Blisters: store blister in its original packaging.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>DETRUSITOL Retard prolonged-release capsules are packaged in PVC/PVDC and aluminium foil blisters with heat-seal PVDC coating or in HDPE bottles with LDPE caps.</p><p>&nbsp;</p><p><em>Packaging</em></p><p>DETRUSITOL Retard 2 mg and 4 mg prolonged-release capsules are available in blisters in packages of 7, 14, 28, 49, 84, 98 and 280 capsules and in bottles of 30, 100 and 200 capsules.</p><p>Hospital packages are available in blisters of 80, 160, and 320 capsules.</p><p><strong><em>&nbsp;</em></strong></p><p>Not all package sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder
Viatris Pharma S.r.l.(Via Vittor Pisani 20, Milano, CAP 20124- Italy ).
Manufacturer 
Pfizer Italia S.r.l., Località Marino del Tronto - 63100 Ascoli Piceno (AP)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2011
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>